Report error Found 311 Enz. Inhib. hit(s) with all data for entry = 7614
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.0730nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.104nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.114nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.135nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.193nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.207nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.214nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.215nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.262nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.267nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.281nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.290nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.300nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.308nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.319nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.330nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.349nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.357nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.367nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.391nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.404nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.417nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.499nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.5nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.501nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.513nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.537nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.547nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.557nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.573nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.582nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.583nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.589nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.596nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.706nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.724nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.724nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.801nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.809nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.837nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.853nMAssay Description:PheG Assay: Two -glucuronidase activity assays were employed to examine the potency of inhibitors both in vitro and in cell-based studies. An absorba...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.872nMAssay Description:PNPG Assay: Two -glucuronidase activity assays were employed to examine the potency of inhibitors both in vitro and in cell-based studies. An absorba...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.875nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.911nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.960nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.979nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 0.988nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 1nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 1.02nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Bayer Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 1.04nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
